In vitro assays performed with the recombinant protein Coversin (Ornithodoros moubata complement inhibitor OmCl) showed that it binds to complement component 5 (C5), selectively preventing proteolytic activation of the terminal lytic pathway of the complement, making it an alternative for use in primary immunodeficiency diseases, such as inappropriate complement activation [138]. The gene discussed is C5; the disease is inborn error of immunity.